Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) in patients undergoing elective cardioversion.
Your search for rivaroxaban returned 154 results
Concomitant use of a nonsteroidal anti-inflammatory drug or aspirin in patients with venous thromboembolism receiving anticoagulant therapy is tied to increased risk of bleeding.
New recommendations have been developed for the optimum management of atrial fibrillation.
Janssen R&D announced the addition of three new clinical trials under the EXPLORER global cardiovascular research program for Xarelto (rivaroxaban) to be evaluated for thromboembolic disorders.
Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.
For patients undergoing lower-extremity arthroplasty, a mobile compression device is noninferior to pharmacological protocols for the prevention of venous thromboembolism.
Cardiac drug interactions make up almost 25% of all preventable adverse drug reactions.
A new pooled analysis of the Phase 3 EINSTEIN trial program showed that Xarelto had similar efficacy as the standard of care in reducing the risk of DVT and PE in patients with symptomatic DVT/PE.
Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care.
Results of a study conducted by Janssen show that prothrombin complex concentrates can reverse the blood thinning effects of Xarelto (rivaroxaban) in healthy subjects.